Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3501
NanoViricides
NNVC
$34.9M
| $90K | ﹤0.01% |
78,600
+7,506
| +11% | +$9.07K |
|
|
ORKA
3502
Oruka Therapeutics
ORKA
$7.11B
| $90K | ﹤0.01% |
3,708
+400
| +12% | +$9.85K |
|
3503
DNA X Inc
SONM
$5.16M
| $89K | ﹤0.01% |
+429
| New | +$83.8K |
|
3504
Orchestra BioMed
OBIO
$266M
| $88K | ﹤0.01% |
+12,600
| New | +$191K |
|
|
TTNP
3505
DELISTED
Titan Pharmaceuticals
TTNP
| $88K | ﹤0.01% |
6,781
+10
| +0.1% | +$153 |
|
3506
Aurora
AUR
$13.5B
| $86K | ﹤0.01% |
29,400
-12,400
| -30% | -$20.8K |
|
3507
Owlet
OWLT
$169M
| $86K | ﹤0.01% |
17,964
+3,900
| +28% | +$16K |
|
3508
Xenetic Biosciences
XBIO
$7.56M
| $85K | ﹤0.01% |
25,782
+15,831
| +159% | +$59K |
|
|
CMLS
3509
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $85K | ﹤0.01% |
20,700
-32,346
| -61% | -$109K |
|
|
AAU
3510
DELISTED
Almaden Minerals Ltd
AAU
| $85K | ﹤0.01% |
658,396
-16,704
| -2% | -$2.27K |
|
|
FGNX
3511
FG Nexus Inc
FGNX
$40.2M
| $84K | ﹤0.01% |
361
-6
| -2% | -$1.62K |
|
3512
Pluri
PLUR
$17.6M
| $84K | ﹤0.01% |
13,150
+262
| +2% | +$1.86K |
|
3513
Eledon Pharmaceuticals
ELDN
$291M
| $83K | ﹤0.01% |
60,373
+28,200
| +88% | +$58.8K |
|
|
CHRN
3514
ChronoScale Holdings
CHRN
$3.02B
| $82K | ﹤0.01% |
3,840
+473
| +14% | +$10.5K |
|
3515
Toro Corp
TORO
$200M
| $82K | ﹤0.01% |
+21,600
| New | +$70.8K |
|
3516
Exicure
XCUR
$8.29M
| $82K | ﹤0.01% |
12,580
-640
| -5% | -$3.3K |
|
|
OTMO
3517
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
| $82K | ﹤0.01% |
13,613
+1,126
| +9% | +$7.16K |
|
|
WKEY
3518
WISeKey
WKEY
$82.2M
| $81K | ﹤0.01% |
18,300
-1,360
| -7% | -$7.74K |
|
3519
Jasper Therapeutics
JSPR
$27.4M
| $80K | ﹤0.01% |
5,810
-5,210
| -47% | -$77.4K |
|
3520
Lineage Cell Therapeutics
LCTX
$278M
| $79K | ﹤0.01% |
+55,900
| New | +$77.2K |
|
3521
MicroSectors FANG & Innovation -3x Inverse Leveraged ETN
BERZ
$15M
| $78K | ﹤0.01% |
+53
| New | +$124K |
|
|
ILPT
3522
Industrial Logistics Properties Trust
ILPT
$605M
| $78K | ﹤0.01% |
+23,510
| New | +$52.5K |
|
3523
Neuropace
NPCE
$496M
| $78K | ﹤0.01% |
17,300
+2,800
| +19% | +$12.7K |
|
|
AMBR
3524
Amber International Holding Ltd
AMBR
$124M
| $78K | ﹤0.01% |
55,603
-9,300
| -14% | -$24K |
|
|
SLNA
3525
DELISTED
Selina Hospitality PLC Ordinary Shares
SLNA
| $78K | ﹤0.01% |
76,416
+21,016
| +38% | +$26.2K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.